Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CBP 501

Next Previous
Drug Profile

CBP 501

Alternative Names: CBP-501; Cdc25C phosphatase (211-221)

Latest Information Update: 30 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CanBas
  • Class Antineoplastics; Peptides
  • Mechanism of Action 14-3-3 protein inhibitors; Calmodulin antagonists; Checkpoint kinase 1 inhibitors; Checkpoint kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Mesothelioma; Non-small cell lung cancer; Pancreatic cancer
  • No development reported Solid tumours
  • Discontinued Ovarian cancer

Most Recent Events

  • 14 Apr 2023 CanBas completes a phase II trial in Pancreatic cancer (Combination therapy, Late-stage disease) in USA (IV) (NCT04953962)
  • 01 Nov 2021 Phase-II clinical trials in Pancreatic cancer (Combination therapy, Late-stage disease) in USA (IV)(NCT04953962)
  • 14 Jul 2021 CanBas plans a phase II trial in Pancreatic cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) (IV) (NCT04953962)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top